Broadfin Capital’s Zimmer Biomet ZBH Stock Holding History

Broadfin Capital’s Portfolio ZBH Stock Details ZBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-206,000	Closed	-$23.4M	–	50
2017 Q3	$23.4M	Buy	+206,000	New	+$23.8M	3.46%	12

Other funds holding ZBH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Longview Partners St Peter Port, Guernsey $7.06B AUM 3.43% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Broadfin Capital's ZBH Position: Q4 2017 in Review

Broadfin Capital sold out of Zimmer Biomet (ZBH) in Q4 2017, closing a stake of 50,470 shares — an estimated $5.74M sold.

Broadfin Capital first reported a position in ZBH in Q4 2016 and held it in 2 quarters. The position peaked at $8.62M in Q4 2016. 870 funds tracked by Wall St. Rank hold ZBH as of Q4 2017.

Broadfin Capital reported no remaining Zimmer Biomet position as of Q4 2017 after selling out during the quarter.
Broadfin Capital sold 50,470 Zimmer Biomet shares in Q4 2017, an estimated $5.74M.
Broadfin Capital first reported a position in Zimmer Biomet in Q4 2016 and held it in 2 quarters.
Broadfin Capital's Zimmer Biomet position peaked at $8.62M in Q4 2016.
870 funds tracked by Wall St. Rank held Zimmer Biomet as of Q4 2017.

Based on Broadfin Capital's 13F filing for Q4 2017, filed 13 Feb 2018.